The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
COVID
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- COVID-19 (127)
- COVID-19 vaccines (80)
- Advertising (76)
- Prescription medicines (33)
- Regulatory compliance (19)
- Alert/Advisory (15)
- Medicine safety (15)
- Safety (7)
- Disinfectants/Sterilants (6)
- Manufacturing (6)
- In Vitro Diagnostic medical devices (IVDs) (5)
- Labelling and packaging (3)
- Over the counter (OTC) medicines (3)
- Australian Register of Therapeutic Goods (ARTG) (2)
- Shortages (2)
- Cosmetics (1)
- Import and export (1)
- Listed medicines (1)
- Medicinal cannabis hub (1)
- Non-prescription medicines (1)
- Scheduling (national classification system) (1)
Collection content
307 result(s) found, displaying 41 to 50
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
NewsThe TGA is aware of concerns about decreased effectiveness of monoclonal antibodies against the COVID-19 caused by emerging SAR-COV-2 variants. At this stage, the regulatory status of the products remain unchanged in Australia.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesOn 17 February, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine. This is the second bivalent vaccine targeting the Omicron BA.4-5 subvariants that has been provisionally approved by the TGA
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has confirmed the performance of COVID-19 rapid antigen tests available on the Australian market with COVID-19 variants.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThis is the first vaccine provisionally approved by the TGA that is designed to specifically target the Omicron variants BA.4/BA.5 and follows provisional approval of the Pfizer BA.1 Omicron/original bivalent vaccine.
-
Media releasesThe TGA has commenced evaluation of an application from Moderna Australia Pty Ltd to transition its COVID-19 vaccine, SPIKEVAX, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older.